Big pharma, Partnering, Pharma

Philogen agrees pharma licensing deal with Pfizer for ADC’s

Posted on 23 December 2014

Tags: , , ,

Philogen entered into a pharma licensing agreement with Pfizer to develop and commercialize empowered antibodies.

According to Philogen, the validated antibodies have precise specificity in diseases characterized by angiogenesis.

Pfizer has exclusive rights to develop certain (antibody-drug conjugates) ADCs and guided nanoparticles.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities

The pharma giant is responsible for R&D and potential commercialization of candidate molecules.

The pharma licensing partnership expands on an existing relationship between the companies from January 2013 when Pfizer obtained rights to Dekavil, an investigational therapy for autoimmune diseases, from Philogen as part of a global license agreement.

For further deal information visit Current Agreements (subscription required)

Related

Scorecard: Top partnering deals by value in 2014

View: Top pharmaceutical companies

View: Top biotech companies

Report:   Top 50 Big Pharma Partnering and M&A Deal Trends

Report:   Top 50 Big Biotech Partnering and M&A Deal Trends

Print Friendly, PDF & Email

Leave a Reply